Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder

Journal of Urology

Volumn 166, Issue 5, 2001, Pages 1633-1638

  Culkin, Daniel J ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Bladder neoplasms; Cell wall; Immunotherapy; Mycobacterium

Indexed keywords

BCG VACCINE;

ARTICLE; BACTERIAL CELL WALL; BLADDER BIOPSY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYSTOSCOPY; CYTOLOGY; DRUG INDUCED DISEASE; DYSURIA; EMULSION; FATIGUE; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034792285     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)65642-x     Document Type: Article

References (40)

1. Treatment of carcinoma in situ of the bladder with BCG
2. BCG for carcinoma in situ
3. Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma
4. Chemoimmunostimulation therapy against a murine leukemia
5. Cytokine induction and tumor suppression in vivo by killed BCG
6. Tumor regression caused by endotoxins and mycobacterial fractions
7. Intralesional administration of microparticulate BCG components: A therapeutic approach for cancer of the prostate
8. The induction of controlled prostatic tissue necrosis by bacille Calmette-Guerin derivatives
9. Immunotherapy of an experimental adenocarcinoma of the prostate
10. Mycobacterium cell wall: An alternative to intravesical bacillus Calmette-Guerin (BCG) therapy in orthotopic murine bladder cancer
11. Effect of mycobacterial cell wall fraction immunostimulant on established line 10 hepatoma in strain 2 guinea pigs
12. Nonspecific immunostimulation against viruses
13. Environmental mycobacteria in bottle table waters in Greece
14. Modulation of cationic liposomal DNA zeta potential and liposome-protein interaction by amphiphilic poly(ethylene glycol)
15. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors
16. The quality of life during bacillus Calmette-Guerin therapy
17. Feasibility, toxicity and biological response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the Children's Cancer Group
18. Intravesical Bacillus Calmette-Guerin therapy for murine tumors: Initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin
19. Bacillus Calmette-Guerin immunotherapy. Techniques and results
20. Principles of intravesical chemotherapy and immunotherapy
21. An overview of the treatment of superficial bladder cancer: Intravesical chemotherapy
22. Intravesical therapy for transitional cell carcinoma of the bladder: The community practice
23. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
24. Immune response following bacillus Calmette-Guerin instillations in superficial bladder cancer: A review
25. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy - A phase I/II study
26. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value
27. Incidence and treatment of complications of BCG intravesical therapy in superficial bladder cancer
28. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer
29. Improving the safety of BCG immunotherapy by dose reduction
30. Low dose vs standard dose BCG therapy of superficial bladder cancer: Final results of a phase III randomized trial
31. Internalization of bacille Calmette-Guerin by bladder tumor cells
32. What are the immunologically active components of BCG in therapy of superficial bladder cancer?
33. Induction of bacillus Calmette-Guerin activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro
34. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and TNF during intravesical immunotherapy with BCG in superficial bladder cancer
35. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells
36. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder
37. Practical approaches to the prevention and treatment of adverse reactions to BCG
38. Comparative genomics of BCG vaccines by whole-genome DNA microarray
39. BCG therapy of superficial bladder cancer: Complications and precautions
40. Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex